Johnson & Johnson's single-shot COVID-19 vaccine candidate meets the standards for emergency use authorization, according to analysis from a committee within the FDA
Johnson & Johnson's single-shot COVID-19 vaccine candidate meets the standards for emergency use authorization, according to analysis from a committee within the FDA, though formal authorization will not be determined until February 26. The vaccine is 66% effective in combating the virus and can be stored in normal refrigerators.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
Johnson & Johnson's single-shot COVID-19 vaccine candidate meets the standards for emergency use authorization, according to analysis from a committee within the FDA, though formal authorization will not be determined until February 26. The vaccine is 66% effective in combating the virus and can be stored in normal refrigerators.